Clinical Trials Logo

Clinical Trial Summary

The most accepted description of severe COVID-19 disease is development and over production of pro-inflammatory cytokines. Autopsy studies have been done on COVID-19 patients proved that severe disease is resulted due to deviant host-immune response and cytokine storm. Elevated inflammatory biomarkers like C-Reactive protein (CRP) and pro-inflammatory cytokines shown to be higher in severe disease of COVID-19. Several studies on severe COVID-19 have revealed raised levels of plasma cytokines like IL-6, IL-2, IL-10, Gamma interferon (INF), Tumor necrosis factor Alpha TNF. The Cytokines release syndrome (CRS) is a hyperinflammatory deadly syndrome characterized by release of uncontrolled immune system activation which is responsible for multi-organ failure. It has the main role in ARDS due to SARS-CoV-2 virus which binds to alveolar epithelium and resulting in IL-6 release that is responsible for increase alveolar-epithelium permeability. In many studies it has been observed that IL-6 have played a main role in CRS induction. Previous experiences from hyperinflammatory and cytokine storm syndromes recommends that early involvement of inhibiting CRS is essential to prevent lethal tissue damage and poor clinical outcome. In this scenario the judgement of clinical specialist who are suggesting that evidence of CRS can be cured with glucocorticoids, I/V immunoglobulin and anti-cytokine therapy cannot be ignored.

Clinical Trial Description

This is intervention single-center study, that will be done at Lahore General Hospital in which 95 beds are allocated for COVID-19 patients including ICUs and HDUs. Ethical approval will be obtained from research ethical committee of Lahore General hospital, Lahore. Informed consent will be obtained from all patients who will agree to publish their data in this research. Patient's privacy and obey will be protected with the Helsinki Declaration. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04560205
Study type Interventional
Source Lahore General Hospital
Contact Muhammad Irfan Malik
Phone 03334367220
Status Recruiting
Phase Phase 1
Start date May 1, 2020
Completion date December 30, 2020

See also
  Status Clinical Trial Phase
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546776 - COVID-19 Persistence in Stool
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Completed NCT04542915 - COVID-19-Related Health and Practices Among Dental Hygienists
Recruiting NCT04615052 - Home-based Exercise in COVID-19 Survivors N/A
Enrolling by invitation NCT04659486 - Adolescents With COVID-19/MIS-C at HCFMUSP N/A
Recruiting NCT04885452 - Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
Completed NCT04516928 - Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel
Completed NCT05063812 - Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
Completed NCT04530357 - Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine Phase 1/Phase 2
Recruiting NCT04565782 - Corona Virus Infection Among Liver Transplant Recipients
Completed NCT04550390 - Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19
Completed NCT04733625 - The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection N/A
Active, not recruiting NCT04517136 - Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions
Recruiting NCT04476680 - Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion N/A
Completed NCT04839913 - Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study
Completed NCT04514874 - Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020
Terminated NCT04606563 - Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? Phase 3
Completed NCT05234359 - The CHILD Cohort COVID-19 Add-On Study